Nuvation Bio (NUVB) 44th Annual J.P. Morgan Healthcare Conference summary

Key product updates and clinical progress

• Ibtrozi (taletrectinib) is approved in the U.S., Japan, and China for advanced ROS1-positive non-small cell lung cancer, showing an 89% response rate and 50-month duration of response, outperforming competitors.

• Safusidenib, a mutant IDH1 inhibitor, is in pivotal studies for gliomas, demonstrating superior progression-free survival and response rates compared to vorasidenib, with unique immune-related adverse events.

• NUV-868, a BD2-selective BET inhibitor, has completed phase I, and a novel drug-drug conjugate (DDC) platform is in preclinical development.

Financial position and strategic partnerships

• Cash balance stands at $589 million, expected to rise to $620 million with a near-term milestone from Eisai.

• Recent Eisai deal for Europe and select territories includes $60 million upfront, $30 million milestone, and high double-digit royalties.

• Additional partnerships in China and Japan have generated $120 million upfront and $520 million in milestones.

• Operating expenses are stable after discontinuing NUV-1511, freeing capital for potential acquisitions of late-stage or commercial assets.

Market opportunity and growth drivers

• U.S. market for ROS1-positive NSCLC estimated at 3,000 patients annually, with potential to reach $5 billion as RNA testing becomes standard.

• Ibtrozi is already the market leader in ROS1 TKIs, with 6x faster launch than competitors and 90% coverage to label.

• NCCN guidelines now contraindicate IO chemo for ROS1 lung cancer, favoring ROS1 agents and supporting further market share gains.

• Safusidenib targets a glioma market with significant prevalence due to long patient survival, and early data suggest a strong competitive profile.